Heclin

Heclin is a HECT E3 ubiquitin ligases inhibitor. Heclin inhibits Smurf2, Nedd4, WWP1 (IC50 values are 6.8, 6.3, 6.9 μM) and can be used for the research of gastric cancer[1][2][3].

Product Specifications

CAS Number

[890605-54-6]

UNSPSC

12352005

Target

Akt; E1/E2/E3 Enzyme; MyD88

Type

Reference compound

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease; PI3K/Akt/mTOR

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/heclin.html

Concentration

10mM

Purity

98.21

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(C(C=C1)=CC=C1NC(/C=C/C2=CC=C(CC)O2)=O)=O

Molecular Formula

C17H17NO3

Molecular Weight

283.32

References & Citations

[1]Wang K, et al. Targeting the E3 ligase NEDD4 as a novel therapeutic strategy for IGF1 signal pathway-driven gastric cancer [J]. Oncogene, 2023, 42 (14) : 1072-1087.|[2]Su B C, Chen J Y. Antimicrobial peptide epinecidin-1 modulates MyD88 protein levels via the proteasome degradation pathway [J]. Marine Drugs, 2017, 15 (11) : 362.|[3]Mund T, et al. Peptide and small molecule inhibitors of HECT-type ubiquitin ligases [J]. Proceedings of the National Academy of Sciences, 2014, 111 (47) : 16736-16741.